SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

"Translating Treg cell therapy for autoimmune disease and transplantation"

Qizhi Tang, PhD

Professor of Surgery and Director of the Transplantation Research Lab
University of California, San Francisco

Tuesday, March 16, 2021 from 4-5 PM

https://yale.zoom.us/j/99742936491?pwd=UkxOSU02RUZ6TDd1bW5kZW95My9WZz09
Password: HTI
Or by telephone: 203-432-9666
Meeting ID: 997 4293 6491

CME Activity Code: Text 22210 to 203-442-9435

Host: Dr. Stephanie Eisenbarth
Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will understand:
1. Why develop Treg cell-based therapy
2. The current state of the field
3. Future directions of Treg cell therapy

FACULTY DISCLOSURES
Qizhi Tang: Received equity/fees from Sonoma Biotherapeutics, eGenesis, Qihan Bio, and Ensulin
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.